What happened to my Valeant shares?

In a column whose chosen focus is on ‘business’ and ‘health care in Canada’, we would be remiss to overlook Valeant. The complex narrative of this precipitous fall is just so rich with fodder. While each step in the saga could serve as a springboard for discussion (mergers and acquisitions, short-seller attacks, senate investigations, price gouging, questionable accounting practices, hedge fund promotion, shocking market share losses, ‘Cold-FX’), it really is more impressive when we run the gamut from start to present. We have been careful not to use the word ‘finish’. The resolution may still be years in the making and this will certainly be out of date by the time of publication. This is a story still unfolding, and with that caveat we will do our best to sort through the themes.